{"filing":{"accession_number":"0001551152-26-000021","cik":"0001551152","ticker":"ABBV","company_name":"AbbVie Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"abbv-20260706.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htm"},"events":[{"id":17100,"run_id":15309,"accession_number":"0001551152-26-000021","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"AbbVie disclosed preliminary Q2 2026 financial results and updated full-year 2026 guidance under Item 2.02, including GAAP and adjusted non-GAAP diluted EPS with a $291 million acquired IPR\u0026D and milestones expense impact. The filing provides revised adjusted diluted EPS guidance ranges for both Q2 2026 ($3.57–$3.61) and full-year 2026 ($13.91–$14.11), with supporting detail in Exhibit 99.1, which is characteristic of an earnings release disclosure.","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15418,"accession_number":"0001551152-26-000021","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AbbVie disclosed preliminary Q2 2026 financial results and updated full-year 2026 guidance under Item 2.02, including GAAP and adjusted non-GAAP diluted EPS with a $291 million acquired IPR\u0026D and milestones expense impact. The filing provides revised adjusted diluted EPS guidance ranges for both Q2 2026 ($3.57–$3.61) and full-year 2026 ($13.91–$14.11), with supporting detail in Exhibit 99.1, which is characteristic of an earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:51:55.327797+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15418,"accession_number":"0001551152-26-000021","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AbbVie disclosed preliminary Q2 2026 financial results and updated full-year 2026 guidance under Item 2.02, including GAAP and adjusted non-GAAP diluted EPS with a $291 million acquired IPR\u0026D and milestones expense impact. The filing provides revised adjusted diluted EPS guidance ranges for both Q2 2026 ($3.57–$3.61) and full-year 2026 ($13.91–$14.11), with supporting detail in Exhibit 99.1, which is characteristic of an earnings release disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:51:55.327797+00:00","company_name":"AbbVie Inc.","ticker":"ABBV","filing_date":"2026-07-06"}]}